IMPROVED ACCESS TO TECHNOLOGY NEEDED FOR PEOPLE WITH TYPE 2 DIABETES NEEDING INSULIN National Diabetes Services Scheme (NDSS) disparity in subsidised access to CGM systems
Australian Health Journal segment
Filmed in Canberra | March 2025
With
Susan Davidson, CEO
Australian Diabetes Educators Association
Sahar Awais,
NSW Registered Nurse
Susan Davidson is the CEO of the Australian Diabetes Educators Association (ADEA), the leading body for diabetes education in Australia. ADEA plays a crucial role in accrediting credentialed diabetes educators and providing essential training for all health professionals, as roughly 25% of individuals seeking healthcare are affected by diabetes.
In Australia, around 1.5 million people are diagnosed with diabetes, with an additional estimated 500,000 undiagnosed cases of Type 2 diabetes. Among those diagnosed, approximately 140,000 have Type 1 diabetes, while 1.3 million live with Type 2 diabetes, and about 65% of these individuals use insulin. The increasing prevalence of diabetes highlights the need for consistent education among healthcare providers to aid patients in managing their conditions effectively.
To address the evolving nature of diabetes management and technology, ADEA has recently introduced micro-credentials for healthcare professionals, enhancing their understanding of diabetes care. Consistent messaging from various healthcare providers is vital, as conflicting information can lead to patient confusion and disengagement from care.
The National Diabetes Services Scheme (NDSS) provides subsidised products for diabetes management; however, disparities exist in access to technology between those with Type 1 and Type 2 diabetes. While continuous glucose monitoring (CGM) devices are subsidised for Type 1, they are not available for Type 2 diabetes. ADEA advocates for equitable access to these essential tools, emphasising that all individuals with diabetes deserve the resources necessary for optimal management and reduced risk of complications. Without such technologies, many are forced to rely on finger pricking, which can be inconvenient and unsafe in settings such as the workplace and in higher education.
Source: Rewritten from transcript
-
Recognising service in health regulation
In April 2023, Professor John Skerritt retired from his position of Deputy Secretary Health Products Regulation Group, a role he has been in since 2012. During his time at the TGA he had line responsibility for over 1200 staff involved in the regulation of therapeutic goods, regulation of gene technology and industrial chemicals and control of drug import, export and production.
At this year’s ARCS 2023 Conference, ARCS Australia CEO Dr Shanny Dyer paid tribute to Professor Skerritt and his service to the Australian health industry. She led a tribute with fellow industry heads, Elizabeth de Somer, CEO, Medicines Australia, Anne Harris, Managing Director, Pfizer Australia & New Zealand, Deon Schoombie, CEO, Consumer Healthcare Products Australia, Ian Burgess, CEO, Medical Technology Association of Australia and Arthur Brandwood, President ARCS Australia.
-
Developing the nation’s first Health and Medical Research Strategy
Professor Steve Wesselingh serves as the CEO of NHMRC, having initially trained as an infectious diseases doctor. His career includes prominent roles such as Head of the Infectious Diseases Unit at the Alfred Hospital, Director of the Burnett, Dean of Medicine at Monash University, and the inaugural Director of SAHMRI. Under his leadership, NHMRC plays a critical role in funding health and medical research, allocating approximately a billion dollars annually to investigator-led projects, clinical trials, and various strategic initiatives. NHMRC also collaborates internationally with organisations such as the MRC and the EU, and manages grant allocation for the MRFF, which distributes $650 million each year.
-
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy.
Australian Health Journal met with 3 speakers at the recent ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
